You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

412 Results
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
ID: PET 2020-2
May 2021
Guidelines and Advice
Status: Current
ID: GL 2-30B
May 2021
Guidelines and Advice
Status: Current
Version: 2
Dec 2024
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pemetrexed,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cladribine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2021
Drug
Other Name(s): Piqray®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
nivolumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024

Pages